Catalyst Pharmaceuticals, Inc.: Firdapse approved for Lambert-Eaton Myasthenic Syndrome (LEMS) with 3Q19 net revenues of $30.9M and FY19 guidance of approx $100M. Key Firdapse trial readouts in 1H20: Phase 3 trial for MuSK-MG and SMA Type 3 proof of concept trial.
Based in...
US - South Atlantic
Clinical Stage
Phase III, Registration Stage
Disease Space
Central Nervous System, Rare Disease
Specialty Pharmaceutical
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Small Molecule
355 Alhambra Circle
Suite 1250
Coral Gables, FL 33134
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Catalyst Pharmaceuticals, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
State Street Corp. 7.23 7,440,822 37.80 13F 2020-03-31
Armistice Capital LLC 5.25 5,400,000 27.43 13F 2020-03-31
The Vanguard Group, Inc. 4.87 5,008,471 25.44 Funds 2020-05-31
Vanguard Group, Inc. (Subfiler) 4.74 4,870,636 24.74 13F 2020-03-31
Mangrove Partners 4.23 4,355,416 22.13 13F 2020-03-31
BlackRock Fund Advisors 3.49 3,591,938 18.25 13F 2020-03-31
BlackRock Institutional Trust Co. NA 2.77 2,853,665 14.50 13F 2020-03-31
Morgan Stanley Smith Barney LLC 2.60 2,673,625 13.58 13F 2020-03-31
Geode Capital Management LLC 1.50 1,541,357 7.83 13F 2020-03-31
Pura Vida Investments LLC 1.41 1,446,953 7.35 13F 2020-03-31
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.